Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648

Lei M.Doki, YuichiroYuichiroDokiKitagawa, YukoYukoKitagawaKato, KenKenKatoChau, IanIanChauYao, JinJinYaoXu, JianmingJianmingXuWyrwicz, Lucjan S.Lucjan S.WyrwiczMotoyama, SatoruSatoruMotoyamaOgata, TakashiTakashiOgataKawakami, HisatoHisatoKawakamiCHIH-HUNG HSUAdenis, AntoineAntoineAdenisHajbi, Farid ElFarid ElHajbiBartolomeo, Maria DiMaria DiBartolomeoBraghiroli, Maria IgnezMaria IgnezBraghiroliHoltved, EvaEvaHoltvedBlum Murphy, Mariela A.Mariela A.Blum MurphyNovosiadly, RuslanRuslanNovosiadlyAjani, Jaffer A.Jaffer A.Ajani2026-01-222026-01-222024-01-010732183Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/735526falseNivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648journal article2-s2.0-105023302684